Imugene (IMU) FDA Meeting Update summary

Regulatory guidance and pathway

• FDA Type C meeting confirmed all major elements for pivotal program, including acceptance of third-line and later DLBCL, and alignment on endpoints for accelerated and full approval.

• FDA guidance allows skipping phase II, moving directly from phase Ib to phase III, reducing regulatory uncertainty and risk.

• Only one randomized study is required for both accelerated and full approval, streamlining the approval process.

• FDA validated the Chemistry, Manufacturing and Controls (CMC) program as registration-ready, with no major bottlenecks anticipated.

• Two approval pathways are available: accelerated approval for faster entry and full approval for long-term success.

Clinical data and product positioning

• Clinical data show an 82% overall response rate in DLBCL patients who failed other treatments, including autologous CAR-T.

• First patient dosed in 2024 remains cancer-free after 19 months, highlighting durable responses.

• Azer-cel offers strong efficacy, clean safety, off-the-shelf scalability, and lower cost of goods compared to autologous therapies.

• Product can expand CAR-T access to more centers and patients, addressing a significant unmet need.

• No current allogeneic CAR-Ts are approved, positioning azer-cel as a first-in-class therapy.

Commercial and operational outlook

• FDA validation fundamentally shifts risk-reward profile, supporting a potential re-rating in market valuation.

• External validation from industry and strong ASH data presentation reinforce product potential.

• Operational focus is on integrating FDA guidance into the study protocol and initiating the registrational study.

• Multiple paths to market are considered, including partnerships or collaborations with pharmaceutical companies.

• Funding strategies include lean study design and potential partnerships to support pivotal program costs.